Charles Newton Sells Shares of KROS
Charles Newton sold 550 shares of KROS on June 11, 2026, as part of planned insider trading activity.
Key Points
- Charles Newton sold 550 shares of KROS at $10.04 each, totaling $5,522, in a planned transaction on June 11, 2026.
- Shares of KROS traded near $10.24, with significant institutional activity including BlackRock increasing its stake.
- Analysts like Wells Fargo have maintained a 'buy' rating on KROS, with price targets up to $27.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Charles Newton, an insider at KROS, sold 550 shares on June 11, 2026. The shares were sold at an average price of $10.04 each, totaling $5,522. This transaction was part of a planned trading activity.
Insider Buying and Selling at Keros Therapeutics, Inc.
Several insiders at KROS have been active in trading recently. On June 4, 2026, Nima Farzan, Julius Knowles, and Alpna Seth each sold 2,625 shares at $10.73. These were also planned sales. On June 3, 2026, Nima Farzan and Jean Jacques Bienaime each purchased 7,142 shares, although the transaction price was not specified, and these were not planned.
Other Institutional Activity in KROS
Institutional investors have also been making moves in KROS. BlackRock, Inc. increased its holdings by 121,261 shares, bringing its total to 2,411,793 shares valued at about $26.6 million. Nantahala Capital Management, LLC made a significant increase, adding 1,000,000 shares, ending with 1,360,419 shares worth approximately $15 million. Meanwhile, Orbimed Advisors LLC and Qube Research & Technologies Ltd reduced their stakes by 45,057 and 58,992 shares, respectively.
Keros Therapeutics, Inc. Stock Down 7.2%
Shares of KROS are trading near $10.24. The stock has seen various institutional movements, reflecting its current position in the market. While the company's financial metrics like P/E ratio and market cap were not provided, the current stock price gives some insight into its market valuation.
Analysts Set New Price Targets
Analysts have been adjusting their outlooks for KROS. On March 5, 2026, Wells Fargo maintained a 'buy' rating with a $20 price target. B of A Securities also maintained a 'hold' rating with a $19 target on November 28, 2025. Oppenheimer reiterated a 'buy' rating with a $27 target earlier on November 12, 2025. These ratings suggest varied expectations for KROS's future performance.
About KROS
KROS is a company actively involved in its sector, though specific details about its operations and leadership were not provided. The company is followed by both institutional investors and analysts, indicating its relevance in the market.
Bottom Line
The recent insider sales at KROS, including Charles Newton's, are part of planned trading activities. Such insider movements are closely watched by investors for potential insights into the company's future. Institutional activity and analyst ratings also play a crucial role in shaping market perceptions of KROS.
Get Keros Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $KROS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.